The INM is located inside the St Eloi Hospital campus, in close contact with IRMB, an institute which host an INSERM unit developing biotherapies. The clinical teams involved in INM translational research (from ENT (Ear, Nose, and Throat), ophthalmology, neurology or neuroradiology) are all located in the Gui de Chauliac hospital which is at a walking distance from the Institute.
The INM is located in the middle of the “Grand Campus” of Montpellier which regroups in the framework of the Montpellier University of Excellence (MUSE) clinical centres and large research institutes. MUSE project gathers the forces of 19 institutions (including INSERM, CNRS and the CHU of Montpellier), towards a common vision: create in Montpellier a thematic research-intensive university that will be internationally recognized for its impact in the fields of agriculture, environment and health. Montpellier is also one of the leading research site in France with the presence of laboratories of excellence (LabEx) such as: the LabEx CheMISyst, within the Balard chemistry cluster, is designed to develop the concept of "system chemistry", the LabEx EpiGenMed which is a multidisciplinary project ranging from genetics and epigenetics to Molecular Medicine, the LabEx MAbImprove dedicated to "better antibodies, best developed, better used", the LabEx ICST which focuses on the Ionic channels of therapeutic interest and the LABEX NUMEV which offers digital solutions, hardware and Modeling for the environment and living. The INM teams are involved in many projects within these Labex.
An important element of the positioning of the INM is also the participation of several teams in the European Center of Excellence in Neurodegeneration of Montpellier (CoEN), which has the specificity of highlighting biomarkers and personalized medicine. The aim of the CoEN is to promote the emergence of multi-disciplinary projects bringing together basic, preclinical, clinical, epidemiological and social sciences on diseases that are major public health issues such as Alzheimer's, Parkinson's disease, multiple sclerosis or amyotrophic lateral sclerosis. INM teams are also involved in the Center of Excellence on Autism and Neurodevelopmental Disorders (CeAND), an interdisciplinary research network aiming to foster interactions between researchers and professionals in the field, families and affected individuals, to promote and disseminate good care and education practices.
The Neuroscience community is also endowed with a University Hospital Federation (FHU) Neuroclin, whose aim is to structure research in Neuroscience in areas where regional expertise is strong (sensory-motor pathologies, neurodegeneration, cognition, psychiatry) to clinical trials, and the creation of companies to develop new drugs or technological devices.
Strong interactions also exists with the Pole of Excellence EUROBIOMED which provides resources and offers solutions for businesses and research organisations in the health sector to help them innovate, finance, develop and achieve their strategic and business objectives to ultimately improve the treatment and the lives of patients. Of note, the INM has a strong activity related to the industry, with 8 patents licensed, 19 filed or accepted, 24 industrial contracts and the recent creation of 5 start-ups.